Results 201 to 210 of about 346,610 (333)

Half-dose may be equivalent to full-dose anticoagulants in preventing venous thromboembolism after primary total joint arthroplasty: a single center comparative retrospective cohort study. [PDF]

Front Pharmacol
Wang Y, Liao Z, Zhou Z, Wang H.
europepmc   +1 more source

Micellar Liquid Chromatography Determination of Edoxaban in Oral Solid Dosage Forms: Theoretical Aspects and Validation

ChemMedChem, EarlyView.
A method is developed and validated to quantify edoxaban in solid oral dosage forms using micellar liquid chromatography. A chemometric strategy is used to study the retention mechanism. The procedure is green, economic, safe, and easy to handle; offers high sample throughput; and is reliable, thus useful for pharmaceutical quality control.
Juan Peris‐Vicente, Devasish Bose, Rajendra‐Pasad Pawar, Abhilasha Durgbanshi, Samuel Carda‐Broch   +4 more
wiley   +1 more source

Therapeutic Plasma Exchange After Spontaneous Intracranial Hemorrhage for a Patient With Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia. [PDF]

J Clin Apher
Nicholas J, Wali J, Ellis-Caleo T, Virk MS, Yunce M.   +4 more
europepmc   +1 more source

Clinical Use of the Anticoagulant Phenylindanedione

, 1952
Frederick W. Preston, WM. R. O'CONNOR, Charles E. Thompson, ELDIS N. CHRISTENSEN   +3 more
openalex   +1 more source

Design and Evaluation of Sticky End‐Type Bivalent DNA Aptamers Containing M08s‐1 as Anticoagulant Agents

ChemMedChem, EarlyView.
Sticky end‐type antithrombin aptamer, composed of two short hybridizable segments, is developed as a potential alternative to conventional anticoagulant drugs. The obtained bivalent aptamer surpasses existing long bivalent aptamers in anticoagulant activity and serum stability, offering advantages in synthesis efficiency and cost‐effectiveness. Aptamer
Maasa Yokomori, Mizuki Murasawa, Muneyuki Matsuo, Masanobu Nagano, Keitaro Yoshimoto   +4 more
wiley   +1 more source

Overcoming NOAC-resistant left atrial appendage thrombus in atrial fibrillation: clinical gaps and therapeutic insights. [PDF]

Front Cardiovasc Med
Nagy KV, Arnóth B, Komlósi F, Gellér L, Merkely B.   +4 more
europepmc   +1 more source

A Guide to Anticoagulant Therapy [PDF]

, 1961
Benjamin Alexander, Stanford Wessler
openalex   +1 more source

Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Zanubrutinib is a next‐generation Bruton tyrosine kinase inhibitor approved for treating B‐cell malignancies. Two phase 1 studies evaluated a new 160‐mg zanubrutinib tablet versus 80‐mg capsules. In study BGB‐3111‐115 (n = 43), a randomized 3‐period crossover trial, relative bioavailability and food effects were assessed.
Bilal Tariq, Chester Lin, Vaibhav Mundra, Yang Gao, Dan Zhang, Ying C. Ou   +5 more
wiley   +1 more source

Intestinal transplantation for patients with short gut syndrome and hypercoagulable states [PDF]

, 2000
Abu-Elmagd, K, Bueno, J, Colangelo, J, Fung, JJ, Giraldo, M, Martin, D, Reyes, J, Starzl, TE   +7 more
core   +1 more source

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu, Hui Shen, Jonathan Greenbaum, Qiao‐Rong Yi, Shuang Liang, Yue Zhang, Jia‐Chen Liu, Chuan Qiu, Lan‐Juan Zhao, Qing Tian, Kuan‐Jui Su, Zhe Luo, Li Wu, Xiang‐He Meng, Hong‐Mei Xiao, Yun Deng, Yang Li, Dragana Lovre, Vivian Fonseca, Fernando L. Sanchez, Li‐Jun Tan, Hong‐Wen Deng   +21 more
wiley   +1 more source